/ /

  • linkedin
  • Increase Font
  • Sharebar

    OASIS study shows positive results for ocriplasmin injection

    Las Vegas—Analyses of data from the OASIS study confirm the efficacy of intravitreal ocriplasmin for the treatment of symptomatic vitreomacular traction/vitreomacular adhesion (VMT/VMA) and the importance of proper patient selection, said Peter K. Kaiser, MD.

    In addition, OASIS provides reassuring information about the safety of ocriplasmin ((Jetrea, ThromboGenics).

    The results, which were presented by Dr. Kaiser, professor of ophthalmology, Cleveland Clinic Lerner College of Medicine, Cleveland, at Retina 2015, showed:

    • OASIS met its primary endpoint with 41.7% of patients treated with ocriplasmin achieving VMT/VMA resolution at day 28 compared with 6.2% of control subjects (p < 0.001)

    • The VMT/VMA resolution rate was even higher in ocriplasmin-treated patients without an epiretinal membrane (ERM) present at baseline (50.6%), but only about 13% in those with an ERM present.  

    • A significantly higher proportion of ocriplasmim-treated patients compared with controls achieved a pre-specified level of improvement in quality of life scores at months 6, 12, and 24.

    • No new safety signals emerged relative to the phase III trial experience

    • Electroretinogram changes after ocriplasmin injection were transient and not associated with long-term effects on visual acuity.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results